Oppenheimer raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $111 from $104 and keeps an Outperform rating on the shares. The firm notes the stock traded higher following Q1 results, as management raised FY26 total revenue guidance and provided an even more bullish outlook for the potential near-term launch of olezarsen in SHTG.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $125 from $120 at H.C. Wainwright
- Ionis Pharmaceuticals price target raised to $115 from $106 at Barclays
- Ionis Pharmaceuticals’ Earnings Call Flags Growth and Risks
- Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook
- Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)